Yüklüyor......
Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAF(V600)-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor
PURPOSE: Preclinical and early clinical studies have demonstrated that initial therapy with combined BRAF and MEK inhibition is more effective in BRAF(V600)-mutant melanoma than single-agent BRAF inhibitors. This study assessed the safety and efficacy of dabrafenib and trametinib in patients who had...
Kaydedildi:
| Yayımlandı: | J Clin Oncol |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
American Society of Clinical Oncology
2014
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4226803/ https://ncbi.nlm.nih.gov/pubmed/25287827 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.57.3535 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|